Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Palisade Bio (Nasdaq:PALI), a clinical-stage biopharma developing once-daily oral PDE4 inhibitor prodrugs for targeted delivery to the terminal ileum and colon, will present at the Jefferies Global Healthcare Conference in New York.
The management presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM ET, with a live webcast and limited-time replay available on the company's investor relations Events page. Management will also hold one-on-one meetings with qualified, registered investors.
Positive
- None.
Negative
- None.
News Market Reaction – PALI
In the May 27 session, PALI gained 4.02%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Neutral | -2.6% | Quarterly results and PALI-2108 clinical progress with strong cash balance. |
| May 05 | Clinical data update | Positive | -7.5% | Additional Phase 1a/b data showing colon-targeted exposure and IC90 coverage. |
| Apr 16 | Conference poster selection | Positive | -0.4% | Poster acceptance at DDW 2026 for PALI-2108 Phase 1 findings in UC. |
| Apr 08 | Investor conference presentation | Neutral | -2.1% | Needham healthcare conference presentation and investor one-on-one meetings. |
| Mar 30 | Phase 1b topline data | Positive | -1.7% | Positive Phase 1b results in fibrostenotic Crohn’s disease for PALI-2108. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and conference-related updates have often been followed by negative price reactions, suggesting a pattern of sell-the-news behavior.
Over the last few months, Palisade Bio has reported multiple milestones around PALI-2108, including positive Phase 1b data on Mar 30 and additional Phase 1a/b analyses on May 5. It also highlighted clinical progress and cash of $132.6M in Q1 results on May 12, and participated in healthcare conferences in April. Despite generally constructive clinical updates, the stock saw negative 24h moves after most of these announcements, pointing to frequent divergence between fundamentals and short-term trading.
Key Terms
pde4 inhibitor prodrugs medical
terminal ileum medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management presentation to take place on Thursday, June 4th at 3:45 PM ET
Register for the webcast here
Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will present at the Jefferies Global Healthcare Conference, being held June 2-4, 2026, in New York, New York.
The Company’s presentation is scheduled for Thursday, June 4, 2026, at 3:45 PM ET. A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered for the conference.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into improved, differentiated oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).
Palisade Bio is now advancing towards Phase 2 clinical studies in UC and Crohn’s disease. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
